In light of these reports and our own findings that Ibrutinib inhibits CXCR4/SDF1 mediated migration in AML we hypothesise that in some AML patients the blast count may initially rise in response to ibrutinib therapy. The gene discussed is CXCR4; the disease is acute myeloid leukemia.